Abstract
Adalimumab is a tumor necrosis factor inhibitor that has been widely used since the early 2000s for the treatment of psoriasis and psoriatic arthritis. All tumor necrosis factor inhibitors have been identified as causative agents in drug induced lupus, particularly etanercept and infliximab. There have been few reported cases of systemic lupus erythematosus induced by adalimumab, many more are attributable to treatment with etanercept or infliximab. We present the case of a patient with long-standing psoriasis and psoriatic arthritis who was successfully treated with adalimumab, but developed anti-tumor necrosis factor-induced lupus.